Friday, March 31, 2023
Clinical Advances in
Glycemic control remains the cornerstone of management of type 2 diabetes (T2D) as it plays a vital role in preventing or delaying the onset and progression of complications. Individualizing therapeutic goals and using modern antihyperglycemic agents when appropriate is crucial to safe and effective management of T2D. These educational activities aim to increase awareness of cardiovascular outcomes data and provide practical strategies to help patients achieve T2D goals using combination therapy.
Supported by
AstraZeneca
Review recently published CV outcome trial data on antihyperglycemic agents, including real-world data on SGLT2 inhibitors.
Download
Steering Committee Chair
Professor, Keck School of Medicine of the University of Southern California; Director, USC Clinical Diabetes Programs, University of Southern California, Los Angeles, California
The Frist Clinic, Nashville, Tennessee
Director, Ochsner Diabetes Clinical Research Unit, Frank Riddick Diabetes Institute, Department of Endocrinology, Ochsner Medical Center, New Orleans, Louisiana
Clinical Professor, University of California at San Diego; Medical Director, Scripps Whittier Diabetes Institute, La Jolla, California
Clinical Professor of Medicine, University of Texas Southwestern Medical Center; Director, Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas
Clinical Professor of Medicine, University of Washington, Spokane, Washington
Steering Committee Chair
has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Becton, Dickinson and Company; Bigfoot Biomedical; Biodel; Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; CVS Caremark; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals; Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Novo Nordisk; Optum Rx; Thermalin
Served as a speaker or a member of a speakers bureau for: Janssen Pharmaceuticals; Lilly
Received grants for clinical research from: Janssen Pharmaceuticals
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lilly; Sanofi
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lilly; Sanofi
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals; Merck & Co., Inc.; Novo Nordisk; Quest Diagnostics; Sanofi
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Janssen Pharmaceuticals; Merck & Co., Inc.; Novo Nordisk; Sanofi
Received grants for clinical research from: Lexicon Pharmaceuticals, Inc.; Lilly; Novo Nordisk; Sanofi
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Halozyme Therapeutics; Janssen Pharmaceuticals; Lilly; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: Janssen Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Halozyme Therapeutics; Janssen Pharmaceuticals; Lilly; Novo Nordisk; Sanofi; Takeda Pharmaceuticals North America, Inc.
Owns stock, stock options, or bonds from: Halozyme Therapeutics
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals; Lexicon Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novo Nordisk; Sanofi
Received grants for clinical research from: Asahi; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; GlaxoSmithKline; Hanmi Pharmaceuticals; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals; Lexicon Pharmaceuticals, Inc.; Lilly; MannKind Corporation; Merck & Co., Inc.; Novo Nordisk; Novartis Pharmaceuticals Corporation; Pfizer Inc; Sanofi; Takeda Pharmaceuticals North America, Inc.
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lilly USA, LLC; Sanofi
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lilly USA, LLC; Novo Nordisk; Sanofi
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals; Lilly USA, LLC; Novo Nordisk; Sanofi